Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHERPA: RMC-4630 and LY3214996 in KRAS-mutant CRC, PDAC, and NSCLC
NCT04916236Phase 1Terminated
- Sponsor
- Netherlands Cancer Institute
- Start
- Mar 2022
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of vociprotafib and temuterkib in colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC) (2 arms), sponsored by Netherlands Cancer Institute. Primary endpoints: Maximum tolerated dose at 2 years and Clinical activity of the RMC-4630 and LY3214996 combination. Started Mar 2022; status: terminated.
02
Drugs
vociprotafibtemuterkib
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT04916236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04916236.